This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Menard, J. Articles by Corvol, P. Search for Related Content PubMed PubMed Citation Articles by Menard, J. Articles by Corvol, P.

Hypertension, Vol 11, 153-159, Copyright © 1988 by American Heart Association

ARTICLES

Crossover design to test antihypertensive drugs with self-recorded blood pressure

J Menard, D Serrurier, P Bautier, PF Plouin and P Corvol
Service d'Hypertension Arterielle, Hopital Broussais, Paris, France.

In a double-blind, within-patient study, blood pressure was measured at regular intervals at the clinic by the physician and each day at home by the patient. Both methods of blood pressure measurement demonstrated an antihypertensive effect of the diuretics chlorthalidone (25 mg) and triamterene (50 mg) and the beta-blocker oxprenolol (160 mg) and the greater efficacy of the combination of the two therapies. During placebo, as well as during active treatment, blood pressure values were higher at the clinic than at home, except when the patients were taking the beta-blocker, which minimized the arousal response during blood pressure measurements in the clinic. With 2-week treatment periods, separated by 2 weeks of placebo administration, blood pressure returned toward its initial level after each of the three treatments and none of the carryover effects was significant at the 5% level. This methodology was intended to make it possible to demonstrate in 27 patients at the clinic and in 20 patients with measurements made at home, at the usual statistical risks (alpha = 5%, beta = 10%), a fall of 5 mm Hg in diastolic blood pressure in comparison with a placebo. Moreover, at the end of this 3-month follow-up, each patient could continue to receive the treatment that was the most effective and the best tolerated. In conclusion, the use of a within-patient trial design, with a 15-day washout period between active treatments and careful recording of blood pressure values, can minimize the number of patients included in hypertension trials and offer to each patient the possibility of individualization of treatment.

This article has been cited by other articles:

				M. J Brown HYPERTENSION: Matching the right drug to the right patient in essential hypertension Heart, July 1, 2001; 86(1): 113 - 120. [Full Text] [PDF]

				L. Fernandes, Z. B. Fortes, D. Nigro, R. C. A. Tostes, R. A. S. Santos, and M. H. Catelli de Carvalho Potentiation of Bradykinin by Angiotensin-(1-7) on Arterioles of Spontaneously Hypertensive Rats Studied In Vivo Hypertension, February 1, 2001; 37(2): 703 - 709. [Abstract] [Full Text] [PDF]

				C. V. Lima, R. D. Paula, F. L. Resende, M. C. Khosla, and R. A. S. Santos Potentiation of the Hypotensive Effect of Bradykinin by Short-term Infusion of Angiotensin-(1-7) in Normotensive and Hypertensive Rats Hypertension, September 1, 1997; 30(3): 542 - 548. [Abstract] [Full Text]

				R. A.S. Santos, A. C. Simoes e Silva, A. J. Magaldi, M. C. Khosla, K. R. Cesar, K. T. Passaglio, and N. C.V. Baracho Evidence for a Physiological Role of Angiotensin-(1-7) in the Control of Hydroelectrolyte Balance Hypertension, April 1, 1996; 27(4): 875 - 884. [Abstract] [Full Text]

				R. D. Paula, C. V. Lima, M. C. Khosla, and R. A.S. Santos Angiotensin-(1-7) Potentiates the Hypotensive Effect of Bradykinin in Conscious Rats Hypertension, December 1, 1995; 26(6): 1154 - 1159. [Abstract] [Full Text]

				G. Chatellier, M. Day, G. Bobrie, and J. Menard Feasibility Study of N-of-1 Trials With Blood Pressure Self-Monitoring in Hypertension Hypertension, February 1, 1995; 25(2): 294 - 301. [Abstract] [Full Text]